Royal Bank Of Canada Onconova Therapeutics, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.67 - $1.01 $180 - $272	-270 Reduced 67.84%	128 $0
Q4 2023 Feb 14, 2024	BUY	$0.62 - $0.79 $118 - $150	191 Added 92.27%	398 $0
Q3 2023 Nov 14, 2023	BUY	$0.71 - $1.15 $114 - $185	161 Added 350.0%	207 $0
Q4 2022 Feb 14, 2023	SELL	$0.63 - $0.97 $28 - $44	-46 Reduced 50.0%	46 $0
Q4 2021 Feb 14, 2022	SELL	$2.49 - $3.73 $12 - $18	-5 Reduced 5.15%	92 $0
Q3 2021 Nov 15, 2021	BUY	$3.81 - $6.76 $369 - $655	97 New	97 $0

276K

Ticker ONTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,895,600
Market Cap $12.3M
Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.